Sun Pharma has settled litigation with Novartis over generic Exelon®
Sun Pharmaceutical Industries Ltd. has executed a settlement agreement with Novartis stipulating a dismissal of the lawsuits filed in the United States against the Company regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Exelon®, rivastigmine tartrate capsules.
Earlier, USFDA had granted final approval for the Company's ANDA to market its generic Exelon®. Under the terms of the settlement agreement, Sun Pharma will not market generic Exelon® in the U.S. until
sometime prior to the expiration of the patents covering Exelon®. The specific date on which Sun may launch and the other terms of the agreement are confidential. Exelon ® is a registered trademark of Novartis.